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Abstract
The aim of the study was to evaluate the effect of a low protein diet (LPD) balanced with essential amino acids (EAA) / keto acid 
analogs (KAA) and protein “SUPRO-XT 219D” in the composition of the high-energy nutrient blend (HENB) for slow down of renal 
failure in patients in the pre-dialysis stage of chronic kidney disease (CKD) induced by systemic autoimmune diseases (SAD).
Material and Methods: In this study, 46 patients (35 with systemic lupus erythematosus and 15 with various forms of systemic 
vasculitis) with CKD in stages 3-4 were randomized into three groups. Group 1 (18 patients: 10 with CKD stage 3 and 8 with  CKD 
stage 4) was given LPD (0.6 g protein per kg of body weight per day comprising 0.3 g of vegetable protein and 0.3 g of animal protein) 
balanced with EAA/KAA (Diet #1); Group 2 (18 patients: 9 with CKD stage 3 and 9 with  CKD stage 4) was given  the same LPD, but 
with an increased vegetable protein content (purified soy protein SUPRO-XT 219D) up to 0.4 g/kg/day in the composition of HENB 
(Diet #2); Group 3, comparison group,  (10 patients: 7 with CKD stage 3 and 3 with  CKD stage 4) was given a free diet (Diet #3) based 
on the patient’s personal preferences. Both options of LPD were offered to all the patients of Groups 1 and 2 regardless of their baseline 
nutritional status (NS). The duration of the observation was 24-48 months.  The NS was evaluated based on the bioelectrical impedance 
analysis. The protein and calorie intake was calculated from the 3-day food diary.
Results: Among the 46 patients with CKD stages 3-4, NS impairment was detected in almost half the patients (45.7%). Both 
forms of LPD were well tolerated. The correction of the nutritive impairment was achieved in patients with baseline impaired NS; the 
remaining patients of Groups 1 and 2 demonstrated the safety of NS against LPD. At the same time, among Group 3 patients, during 
the progression of renal disorders, the NS rate was observed to increase by 1.5 times (from 40% to 60%). Slowing down the glomerular 
filtration rate (GFR) decline was observed in the patients treated with LPD for at least a year, which was more significant in the subgroup 
fed with the increased quota of vegetable protein SUPRO-XT 219D.
Conclusion:  Early restriction (on pre-dialysis stage) of the protein intake (0.6 g/kg/day) supplemented with HENB and EAA/
KAA revealed a positive effect on the NS of CKD patients and was found to be able to slow down the GFR decline.
Keywords: systemic autoimmune diseases; chronic kidney disease; impairment of  nutritional status; essential amino acids; keto acid 
analogs; SUPRO-XT 219D.
CLINICAL RESEARCH
Introduction
One of the major problems in nephrology is a warning for 
maximum decline in the end-stage of CKD with very limited 
possibilities to influence the expression of the disease.
The  progression  rate  of  renal  failure  in  CKD  patients 
depends on several factors, including the violation of NS, which 
significantly  effects  the  survival  and  the  rehabilitation  level 
of  the  patients  and  has  an  important  prognostic  value  [1-4]. 
Thus, according to Zakar G. [5], the mortality during the first 
year of dialysis was 15% among those patients whose serum 
albumin concentration at admission on hemodialysis was above 
3.5 g/dl and 39% among those patients with a serum albumin 
concentration of less than 3.0 g/dl.
Over the recent years, a growing interest in the dietary 
treatment of patients in the pre-dialysis stages of CKD (PDS-
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CKD) has been observed. A few studies have shown that limiting 
the daily quota of protein to 0.6 g/kg/day with the addition of 
EAA/KAA  prevented  the  accumulation  of  toxic  products  and 
reduced or postponed the development of terminal uremia [5-7]. 
However, the results of several multicenter studies with larger 
numbers of participants, including the MDRD (Modification of 
Diet in Renal Disease), do not provide a solid reason for such 
a clear conclusion [8-10]. The differences in the results can be 
explained by the complexity in the LPD organization, particularly 
large-scale ensuring of the sufficient quota of high biological 
value protein and caloric intake (at least 35 kcal/kg/day). With 
the  energy  deficit,  there  is  an  impairment  of  the  EAA/KAA 
absorption in the gastrointestinal tract and the transformation of 
KAA in EAA [11,12].
The difficulties of prolonged LPD use, the mixed results 
of its effectiveness, spontaneous reduction of protein and calorie 
consumption due to the decreased appetite at the onset of the 
deterioration of the renal function, indicate the need for further 
clinical study regarding the influence of diet in renal failure.
The reasons for the high frequency of NS impairment in 
patients  with  systemic  disease  on  PDS-CKD  are  still  poorly 
studied.
We conducted our own study to assess the impact of LPD 
balanced  with  EAA/KAA  and  HENB  based  on  SUPRO-XT 
219D on the slowing of renal failure in patients with SAD on 
PDS-CKD.
Material and Methods
In  this  study,  46  patients  (35  with  systemic  lupus 
erythematosus and 15 with various forms of systemic vasculitis) 
with  CKD  in  stages  3-4  were  randomized  into  three  groups 
(Table 1). Group 1 (18 patients: 10 with CKD stage 3 and 8 
with  CKD stage 4) was given LPD (0.6 g protein per kg of body 
weight per day comprising 0.3 g of vegetable protein and 0.3 g of 
animal protein) balanced with EAA/KAA (Diet #1); Group 2 (18 
patients: 9 with CKD stage 3 and 9 with  CKD stage 4) was given   
the same LPD, but with an increased vegetable protein content 
(purified soy protein SUPRO-XT 219D) up to 0.4 g/kg/day in 
the composition of HENB (Diet #2). EAA and KAA (Ketosteril; 
Fresenius Kabi, Germany; daily dose 0.1 g/kg) was additionally 
administered to the LPD in the patients of Groups 1 and 2. Group 
3, comparison group, (10 patients: 7 with CKD stage 3 and 3 with   
CKD stage 4) was given a free diet (Diet #3; 1.1-1.3 g protein 
per kg of body weight per day) based on the patient’s personal 
preferences. 
The mean daily caloric content of the LPD in Group 1 was 
33 kcal/kg. Nutrient blend “Peptoproten Nephro” (ProtenPharma, 
Russia) was used as a dry powder for the cocktail (17g of highly 
purified soy protein, including protein hydrolysate 4 g per 100 g 
powder) or bars (12 g of soy protein, including protein hydrolysate 
2 g per 50 g bar). The composition also includes slowly absorbed 
carbohydrates (maltodextrin) and vegetable fats (soybean, palm), 
vitamins B and E, folic acid, nicotinamide, calcium pantothenate, 
L-carnitine  and  dietary  fiber. The  total  caloric  content  of  the 
nutrient blend was 405 kcal (1693 kJ) per 100 g.
The groups were equal in terms of severity of the blood 
pressure  and  proteinuria.  Antihypertensive  therapy  included 
fosinopril 5-10 mg/day and loop diuretics.
Recurrent  nephritis  was  found  to  occur  in  the  patients 
surveyed.  To  study  NS,  bioelectrical  impedance  analysis  and 
laboratory  tests  (an  absolute  lymphocyte  count,  albumin  and 
transferrin levels) were used. The protein and calorie intake was 
calculated from the 3-day food diary, where the patient recorded, 
in  detail,  his  daily  diet  by  indicating  the  protein  and  calorie 
content.
Statistical analysis of the study results performed using the 
SPSS 10 software package for Windows. Frequencies of individual 
values, mean, standard deviation of the mean, Student’s t-test, 
confidence level, and the level of significance p were calculated. 
The Mann-Whitney (U Test) was used to compare the differences 
between the two independent groups (for nonparametric data). 
The value of p less than 0.05 was considered significant.
In  the  calculation  of  renal  survival,  the  decrease  in 
eGFR<15ml/min/1.73m²  or  the  commencement  of  renal 
replacement therapy was considered the endpoints. 
Result and Discussion
The NS impairment was detected in almost half the patients 
(21/45.7%) (Table 2). However, nutritive impairment was detected 
only at CKD stage 4 in patients with chronic glomerulonephritis, 
but it appeared at CKD stage 3 in all the patient groups with SAD 
and increased with the progression of renal failure to CKD stage 
4 [12].
Previously, we demonstrated the influence of a low-calorie 
diet, the severity of renal failure, high proteinuria, and the duration 
of corticosteroid therapy in SAD on the reduced BMI, which is 
the integral index of nutritive impairment in CKD patients [12].
In the present study, Diets #1 and #2 were administered to 
all the Group 1 and 2 patients, respectively (regardless of NS and 
without its prior correction). We had to contend with two major 
issues.  Could  LPD  supplemented  with  EAA/KA  (Ketosteril; 
Table 1. 
Distribution of patients according to CKD stage 
Groups CKD stage 3
(eGFR: 59-30 ml/
min/1.73 m²)
CKD stage 4
(eGFR:2 9-15 ml/
min/1.73 m²)
Number of patients
Group I, n=18;
Diet #1
10 8
Group 2, n=18;
Diet #2
9 9
Group 3, n=10;
Diet #3 (free diet)
6 4
Total 25 21
Table 2. 
Nutritional status impairment in patients with CKD stages 3-4 
Groups CKD stage 3
(eGFR: 59-30 ml/
min/1.73 m²)
CKD stage 4
(eGFR: 29-15 ml/
min/1.73 m²)
Number of patients 
Group I, n=18 40% (4/10) 62.5% (5/8)
Group 2, n=18 33.3% (3/9) 55.5% (5/9)
Group 3, n=10 33.3% (2/6) 50% (2/4)
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Fresenius  Kabi,  Germany;  daily  dose  0.1  g/kg)  adjust  and 
prevent NS impairment in patients with SAD, and slow down 
the progression of CKD? Is it possible to increase the beneficial 
effects of LPD through a partial replacement of animal protein on 
HENB comprising soy isolate (SUPRO-XT 219D)?
Diets  #1  and  #2  were  satisfactorily  tolerated,  as 
documented in the three-day food records. Satisfactory tolerance 
of diet explained the treatment compliance. Thus, the majority 
of patients were taking Diets #1 and #2 for long periods (over 
1.5 years). In this case, the intake Diets #1 and #2 in patients 
with anorexia resulted in its significant decrease. Anorexia was 
decreased, primarily, in patients with a partial replacement of 
animal protein on highly purified soy protein in the diet. As a 
result, after three months’ treatment of employing these diets, 
normalization of the main indicators of the NS was achieved in 
those patients with initial NS impairment. The effectiveness of 
the diets was observed in both women and men. Normalization 
of body weight and other NS parameters occurred more quickly 
in patients treated with Diet #2 and the change in the nutritive 
indicators at the end of three months was more significant than 
with Diet #1 (Table 3).
During  the  same  period  of  observation,  the  increased 
nutritive impairment and the deterioration of health, despite a 
free diet without protein restriction, were observed in 10 patients 
of the control group, including four patients with NS impairments 
of an initial degree. As the progression of renal disease increased 
the frequency of NS impairment increased by 1.5 times (from 
40% to 60%) in patients with CKD stage 4.
To assess the effect of LPD on the progression of chronic 
renal failure, we compared the GFR curve decline in patients 
treated with Diets #1 and #2 with that of the patients of the 
comparison group on a regular diet (Table 4, Fig.1). By the end 
of one year of observation, the GFR curve decline was close to 
the estimated index (4 ml/min/year) in 10 patients of the control 
group. Two of the three patients of the control group received 
hemodialysis at the end of 1.5 years.  In patients treated with 
LPDs, for at least a year, the GFR curve decline compared with 
the estimated GFR was about 0.75 ml/min/year in patients treated 
with Diet #1 and 0.8 ml/min/year on Diet #2. 
 Based on these calculations, one can assume that a 4-year 
use of Diets #1 and #2 in patients with CKD stage 4 and an initial 
GRF of 26 ml/min will lead to an increase in the pre-dialysis 
period by 11 months and 12 months, respectively.
  A  significant  reduction  in  hyperphosphatemia  was 
observed  in  all  the  36  patients  taking  KAA,  which  contain 
calcium  salts  (without  phosphorus)  that  promote  the  binding 
of  the  phosphate  in  the  intestine  and  its  removal  from  the 
organism.  Decreasing  the  severity  of  hyperphosphatemia  in 
patients with CKD stages 3-4 becomes very important. As is 
known,  hyperphosphatemia  causes  increased  secretion  of  the 
parathyroid hormone with hypercalcemia and the development 
of  secondary  hyperparathyroidism  [1,13,14].  The  decrease  in 
hyperphosphatemia  was  more  significant  among  the  Group  2 
patients; therefore, replacing animal protein with highly purified 
soy protein having low phosphate content can more effectively 
control  the  hyperphosphatemia  and  prevent  the  development 
of  secondary  hyperparathyroidism.  At  the  same  time,  the 
hyperphosphatemia was increasing in all the 10 patients of the 
comparison  group, who did not limit the protein in their diet and 
were not given Ketosteril (Table 5).
Table 3.
Dynamics of changes in NS parameters in patients with CKD stages and 
initial NS impairment on LPD (n=17)
Parameter Diet #1 (n=9) Diet #2 (n=8)
Baseline After
 3 months     
Baseline After
 3 months     
BMI
(kg/m2)
17.9±0.35 
(18.9-15.0)
19.5±0.33 
1.6 (23-18.4)
17.6±0.21
(17.9-15.1)
20.0±0.29* 
2.4 (21.5-18.9)
Muscle 
mass (%)
28.9±0.3
(27.6-30.0)
36.4±0.62*
(38.0-32.0)
28.5±0.5 
(27.8-29.9)
37.1±0.85**
(39.1-31.1)
Serum 
albumin (g/l)
32.0±1.2
(35-30)
38.0±0.9* 
(41-35)
29±1.1
(32-28)
37.0±0.8* 
(38-35)
Serum  trans-
ferrin (mg/dl)
169.7±2.03
(175-164)
190.3±2.3* 
(195-186)
163.5±2.95
(169-158)
196.4±3.38*
(200-190)
Lymphocytes
(abs. number)
1689.3±21.3
(1750-1618)
1895.3±26.2*
 (1956-1830)
1433.5±115.9
(1655-1218)
1931.3±38.4**
 (200-1830)
*P <0.05, **P<0.01 vs baseline
Table 4. 
Effect of LPD on the progression of chronic renal failure in patients with 
CKD stage 4
Diet options/ 
N of patients
eGFR
(59-30 ml/min/1.73 m²)
Period of observation (years)
Screening 0.5 1.0 1.5
Diet #1 
(n=18)
26.4±0.21 24.8±0.41
∆1.6
23.1±0.17
∆3.3
21.6±0.19
∆5.0
Diet #2 
(n=18)
26.5±0.33 24.9±0.32
∆1.6
23.3±0.27
∆3.2
22.0±0.23
∆4.5
Diet #3
 (n=10)
26.8±0.22 24.7±0.29
∆2.1
22.8±0.35
∆4.0
20.6±0.25
∆6.2  P<0.05
   ∆ - GFR curve decline
Table 5.
Effect of LPD on hyperphosphatemia and hyperazotemia in patients with 
CKD (n = 36)
Parameter Control Diet #1 (n=18) Diet #2 (n=18)
Baseline After 
12 months
Baseline After 
12 months
Serum
phosphorus
(mg/dl)
2.5-5.5 6.8±0.55
(5.8-7.8)
5.0±0.29**
(4.5-5.8)
6.9±0.42
(5.7-7.9)
4.7±0.23**
(4.0-5.2)
Serum
urea nitrogen 
(mg/dl)
10-12 67.4±5.11
(35-30)
53.8±4.04*
(45-60)
69.7±3.12
(65-74)
48.2±2.03**
(55-75)
*P <0.05, **P<0.01 vs baseline
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 Our data are consistent with the results of Mitch W. et al., 
who noted the possibility of achieving reutilization of the urea 
nitrogen for the synthesis of EAA from the KAA with a reduction 
of azotemia on the intake of LPD and KAA [15]. 
The results of this study indicate that the LPD balanced with 
the EAA/KAA and highly purified soy protein over prolonged 
use  (at least 12 months) caused a reduction in the levels of 
total cholesterol and LDL cholesterol, triglycerides, and HDL 
cholesterol increasing in the plasma, in 36 patients (18 patients of 
Group1 and 18 patients of Group 2) with dyslipidemia.
According to some data [1,7], the LPD balanced with EAA/
KAA  and  highly  purified  soy  protein  caused  other  metabolic 
effects  such  as  a  reduction  of  urinary  albumin  excretion,  a 
reduction in the concentration of oxalic acid, free radicals, and an 
increase in the testosterone levels and vitamin D3 in the plasma. 
All these effects slowed the progression of atherosclerosis and 
reduced the manifestations of renal osteodystrophy, according to 
bone biopsy [1,14].
Conclusion
Thus,  NS  impairment  is  one  of  the  most  frequent 
complications in CKD patients with SAD, which reaches 36% at 
stage 3 and 57% at stage 4. Among those patients with chronic 
glomerulonephritis, the NS impairment was detected only at stage 
4 in 28.3% of cases [12,16]. The high risk of NS impairment in 
patients with SAD is caused by the factors of the disease activity 
and the duration of the corticosteroid treatment.
The primary prevention of malnutrition in patients with 
CKD  at  stages  3-4  traditionally  includes  the  restriction  of 
dietary protein intake with the addition of EAA/KA intake. The 
LPD balanced with the EAA/KA prevents the accumulation of 
toxic products, reduces or postpones the appearance of uremic 
dyspepsia, while a diet without protein restriction, exacerbating 
dyspepsia, is capable of inducing the NS impairment [1, 7, 13]. 
The  results  of  our  study  indicate  that  the  intake  of 
vegetable protein of high biological value (SUPRO-XT 219D) is 
a prospective way for nephroprotection in PDS-CKD. The ratio 
of dietary animal protein to highly purified soy protein (SUPRO-
XT 219D) may depend upon the patients’ food tastes and habits. 
According to our data, it was appropriate to increase the content of 
highly purified soy protein up to 0.3 g/kg/d in patients committed 
to using mostly vegetable protein, as well as in anorexic patients. 
Soy protein increases the hyperperfusion and hyperfiltration in 
the remnant nephrons less than animal protein (meat, fish, milk, 
etc) [12]. According to our data, the LPD (0.6 g protein per kg of 
body weight per day) with partial replacement of animal protein 
on HENB with the addition of EAA/KAA allows the slowing 
down of the GFR decline by 0.8±0.03 ml/min/1.73 m² and ensures 
the prevention of malnutrition in patients with CKD caused by 
SAD. This LPD version is recommended for patients with CKD 
stage 4 and digestive disorders caused by uremia; these dietary 
recommendations must be applied in patients with SAD, starting 
with CKD stage 3, if the disease is actively persistent.
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